Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The FDA approval marks the first drug approved for Azurity, a company formed from the merger of CutistPharma and Silvergate.
The U.S. Centers for Disease Control and Prevention published research in the journal Lancet Infectious Diseases outlining the results from two experimental Ebola drugs, Gilead Sciences’ remdesivir and Mapp Biopharmaceutical’s ZMapp. Both successfully inhibited the growth of the virus in human cells in laboratory studies.
Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, announced preliminary financial results for the quarter ended June 30, 2019.
Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that it will release financial results for the second quarter 2019 after the close of trading on Tuesday, August 6.
Reston Hospital Center has received the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Gold Plus Quality Achievement Award.
Biofrontera AG, an international biopharmaceutical company, reports preliminary unaudited revenue for the first six months of fiscal year 2019.
Cellectar Biosciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma.
CorMedix Inc. announced that it has received feedback from the U.S. FDA regarding the submitted statistical analyses of data and additional information requested by the FDA for the primary and secondary efficacy endpoints of the Company’s LOCK-IT-100 clinical study.
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites